Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

JNJ

JOHNSON & JOHNSON

Pharmaceutical Preparations · SIC 2834CIK 200406Held by 26 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$94.19B
Net Income FY2025
$26.80B
EPS (Basic, as reported)
$11.13
Net Margin FY2025
28.5%
ROE FY2025
32.9%
Total Equity
$81.54B
Shares Out
2.41B
Business description

JOHNSON & JOHNSON — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2007–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 74,331 → 94,193 +2.7% CAGR
Fiscal yearFY2014FY2016FY2017FY2018FY2019FY2021FY2022FY2023FY2024FY2025
Revenue74,33170,07471,89081,58182,05982,58493,77594,94388,82194,193
Cost of revenue(22,746)(21,536)(25,439)(27,091)(27,556)(28,427)(29,855)(31,089)(27,471)(30,256)
Gross profit51,58548,53850,20554,49054,50354,15763,92063,85461,35063,937
Research & development——————0(483)(1,841)(109)
Selling, general & administrative(21,954)(21,203)(19,945)(22,540)(22,178)(22,084)(24,659)(24,765)(22,869)(23,676)
Operating income21,590—————————
Interest expense(533)(552)(726)(1,005)(318)(201)(183)(276)(755)(971)
Interest & investment income67128368611357111534901,3321,056
Other income (expense), net702,064(484)(1,405)(2,525)(2,899)(489)(1,871)(4,694)7,209
Pre-tax income20,56319,19619,80317,99917,32816,49722,77621,72516,68732,581
Income tax expense(4,240)(3,787)(3,263)(2,702)(2,209)(1,783)(1,898)(3,784)(2,621)(5,777)
Net income16,32315,40916,54015,29715,11914,71420,87817,94114,06626,804
EPS — basic$5.80$5.56$6.04$5.70$5.72$5.59$7.93$6.83$5.84$11.13
EPS — diluted$5.70$5.48$5.93$5.61$5.63$5.51$7.81$6.73$5.79$11.03
Shares outstanding — basic (M)2,8152,7722,7372,6822,6452,6332,6322,6252,4072,407
Shares outstanding — diluted (M)2,8642,8132,7892,7292,6842,6712,6742,6642,4292,429

Showing the latest 10 of 16 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.